Alunbrig Approval History
FDA Approved: Yes (First approved April 28, 2017)
Brand name: Alunbrig
Generic name: brigatinib
Dosage form: Tablets
Company: Takeda Pharmaceutical Company Limited
Treatment for: Non-Small Cell Lung Cancer
Alunbrig (brigatinib) is an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) non-small cell cancer (NSCLC) whose disease is resistant to crizotinib.
Development History and FDA Approval Process for Alunbrig
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.